Daclizumab Shows Promise in Multiple Sclerosis TrialFamily Practice News Digital NetworkAMSTERDAM – Daclizumab reduced the rate of relapse and the rate of disability progression in patients with relapsing-remitting multiple sclerosis in a 1-year, pla…
Daclizumab Shows Promise in Multiple Sclerosis TrialInternal Medicine News Digital NetworkAMSTERDAM – Daclizumab reduced the rate of relapse and the rate of disability progression in patients with relapsing-remitting multiple sclerosis in a 1-year, p…
Cancer Drug Shows Promise for Chronic Fatigue SyndromeAbout – News & IssuesNew research suggests that the cancer drug Rituxan (rituximab) may be an effective treatment for chronic fatigue syndrome. The findings also add support to the theory that chron…
Proactive Investors USA & CanadaBiogen Idec (BIIB) Announces Quarterly ResultsLocalizedUSAIn addition to the marketed products, Biogen Idec has a number of product candidates in or near registrational stage development. It includes BG-12, Daclizumab, F…
Biogen Idec's CEO Discusses Q3 2011 Results – Earnings Call TranscriptSeeking AlphaAdditional news this quarter from our late-stage pipeline, including data presented at last week's ECTRIMS meeting for SELECT, the first of 2 registrational tria…
Biogen Idec Reports Third Quarter 2011 ResultsMarketWatch (press release)Therapies in Biogen Idec's MS franchise presented at the conference included TYSABRI, BG-12, FAMPYRA(R) (prolonged-release fampridine tablets), AVONEX, and daclizumab high-yie…
XMRV (HGRV) is Not Dead – The Rituximab StoryAge of AutismApology from the Norwegian Directorate of Health on publication of a study showing that the cancer drug rituximab is effective in the treatment of chronic fatigue syndrome/ME. What was reason fo…
Promising Results for Daclizumab High-Yield in MSMedscapeOctober 27, 2011 (Amsterdam, the Netherlands) — Full results of the SELECT trial comparing 2 doses of daclizumab high-yield process (Biogen Iden/Abbott) with placebo confirm that both doses red…
Proactive Investors USA & CanadaBiotech Investing Lessons Learned: Diversify, Be PatientSeeking AlphaIn Biogen's case, results are for daclizumab for multiple sclerosis and for BG-12 for MS as well. Onyx's results are for regorafenib for metast…
Authority EmpireRituximab – A Cancer Drug – May Treat Sufferers Of Chronic Fatigue SyndromeAuthority EmpireNorway researchers report that they can treat Chronic Fatigue Syndrome with the cancer treatment drug Rituximab (Rituxan), which is a biologi…